The human brain is a complex network of billions of interconnected cells, organized in many networks communicating with one another. Some CNS disorders arise from dysregulation in the modulation of these networks, either by altered levels of signaling molecules like neurosteroids or the receptors they target. Boosting the brain’s natural [...]
Neurosteroids, like allopregnanolone (ALLO), are natural signaling molecules made in the brain from cholesterol and are essential for normal brain biochemistry. They can induce potent anxiolytic, antidepressant, anticonvulsant, and analgesic effects, mainly through interaction with the GABA channel, the main inhibitory system in the brain. In addition to these psychopharmacological [...]
Over 40 years of research and clinical data on etifoxine (and therefore GRX-917) has shown that the drug has little to no side effects: No Sedation (some people say slight sedation on day one which quickly remits) No Cognitive Impairment No Ataxia
Etifoxine (and therefore GRX-917) has been shown through multiple published, peer reviewed clinical studies, to have comparable rapid onset and efficacy to leading benzodiazepines, including like alprazolam (Xanax™) and lorazepam (Ativan™).
GRX-917's main mechanism of action increases the amount of naturally occurring neurosteroids (like allopregnanolone) by activation of TSPO on mitochondria. This increase of endogenous neurosteroids occurs in areas in the brain where they are used to activate GABA receptors, slowing dysregulated brain activity in diseases like anxiety and depression, but [...]
GRX-917 is a proprietary (patent-protected until 2036), improved version of Etifoxine, an anxiety drug first approved in France 39 years ago. GRX-917 is a deuterated version of Etifoxine (specific hydrogen atoms were replaced by isotopic deuterium (heavy hydrogen) atoms). Like the vast majority of deuterated drug analogs, GRX-917 retains the [...]